Tag: Vaccines

Higher rates of vaccination seen in older patients; lower rates seen for metastatic solid tumors, with comorbidities

No significant associations seen for age, vaccine booster type, history of breast cancer with time to resolution

Findings significant for both partial and complete COVID-19 vaccination

In two-part vote, panel voted 10 to 2 in favor of the vaccine's safety and unanimously on the shot's effectiveness

Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86 percent

Vaccine effectiveness 54 percent against medically attended outpatient acute respiratory infection associated with influenza A in patients younger than 65 years

Parents report a mix of factors, including scientific evidence and political and social pressures, influencing their decision

High vaccine efficacy seen against RSV A and B subtypes, across age groups among those aged 60 years and older, and for those with coexisting conditions

Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions

The U.S. public health emergency declaration is scheduled to end in May